Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 27, Issue 2, pp. 394-401
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 19, 2020
- Revision received October 8, 2020
- Accepted November 10, 2020
- Published first November 13, 2020.
Article Versions
- Previous version (November 13, 2020 - 06:18).
- Previous version (December 30, 2020 - 06:10).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Kristen L. Mueller1,
- Marc R. Theoret2,
- Steven J. Lemery2,
- Laleh Amiri-Kordestani2,
- Charlotte E. Ariyan3,
- Michael B. Atkins4,
- Donald A. Berry5,
- Christian U. Blank6,
- Angela M. DeMichele7,
- Patrick M. Forde8,
- Nageatte Ibrahim9,
- Patricia Keegan2,
- Tara C. Mitchell7,
- Rebecca A. Moss10,
- Caroline Robert11,
- Rajeshwari Sridhara2,
- Janis M. Taube8,
- Michael T. Tetzlaff5,
- Jennifer A. Wargo5,
- Keith T. Flaherty12,
- Michael J. Kaplan1,
- Suzanne L. Topalian8,
- Ashley F. Ward2, and
- Marc S. Hurlbert1,*
- 1Melanoma Research Alliance, Washington, DC.
- 2U.S. Food and Drug Administration, Silver Spring, Maryland.
- 3Memorial Sloan Kettering Cancer Center, New York, New York.
- 4Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.
- 5University of Texas MD Anderson Cancer Center, Houston, Texas.
- 6Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 7University of Pennsylvania, Philadelphia, Pennsylvania.
- 8Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland.
- 9Merck, Inc., Kenilworth, New Jersey.
- 10Bristol Myers Squibb, Lawrenceville, New Jersey.
- 11Insitut Gustave Roussy and Paris-Saclay University, Villejuif, France.
- 12Massachusetts General Hospital, Boston, Massachusetts.
- ↵*Corresponding Author:
Marc S. Hurlbert, Melanoma Research Alliance, 730 15th Street NW, 4th Floor, Washington, DC 20005. Phone: 202-336-7230; E-mail: mhurlbert{at}curemelanoma.org
January 2021
Volume 27, Issue 2
Volume 27, Issue 2
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Jump to section
- Article
- Abstract
- Introduction
- Lessons Learned from Neoadjuvant Therapies in Other Cancers
- Neoadjuvant Melanoma Trials
- Integration of Systemic Neoadjuvant Therapy with Surgery
- Neoadjuvant Clinical Trial Design and Regulatory Considerations
- Challenges and Future Research Directions in Neoadjuvant Treatment for Melanoma
- Conclusions
- Authors’ Disclosures
- Disclaimer
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement